NCT00425698View on ClinicalTrials.gov

Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

November 30, 2009

Conditions
Kidney Transplantation
Interventions
DRUG

Recombinant erythropoietin alpha (rHuEPO alpha)

Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation

DRUG

Placebo

Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation

Trial Locations (1)

30625

Hannover Medical School, Hanover

All Listed Sponsors
lead

Hannover Medical School

OTHER

NCT00425698 - Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation | Biotech Hunter | Biotech Hunter